Escalon Medical Corp.  

(Public, NASDAQ:ESMC)   Watch this stock  
Find more results for ESMC
1.20
+0.07 (6.18%)
May 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.15 - 1.20
52 week 0.25 - 1.25
Open 1.15
Vol / Avg. 7,100.00/1,518.00
Mkt cap 9.03M
P/E     -
Div/yield     -
EPS -0.16
Shares 7.53M
Beta -0.02
Inst. own 8%
May 14, 2013
Q3 2013 Escalon Medical Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -10.41% -10.87%
Operating margin -10.82% -9.14%
EBITD margin - -7.19%
Return on average assets -14.55% -19.67%
Return on average equity -24.70% -77.76%
Employees 118 -
Carbon Disclosure Rating - -

Address

Bldg 100, 435 Devon Park Drive
WAYNE, PA 19087
United States - Map
+1-610-6886830 (Phone)
+1-610-6883641 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Escalon Medical Corp. (Escalon), operates in the healthcare market, specializing in the development, manufacture marketing and distribution of medical devices and pharmaceuticals in the areas of ophthalmology, diabetes and hematology. The Company�s segments include Escalon Clinical Diagnostics (ECD), Sonomed-Escalon and Escalon Medical Corp. The Escalon Clinical Diagnostics (ECD) segment consists of Drew Scientific, Inc., and its wholly owned subsidiaries JAS Diagnostics, Inc. (JAS) and Biocode Hycel (Biocode). The Sonomed-Escalon segment consists of Sonomed, EMI and Trek, all of which are engaged in the development and sale of Ophthalmic medical devices. The Escalon Medical Corp. segment includes the administrative corporate operations of the consolidated group. In October 2012, ERBA Diagnostics, Inc. acquired the Clinical Diagnostics Business from Escalon.

Officers and directors

Richard J. DePiano Jr. President, General Counsel, Director
Bio & Compensation  - Reuters
Richard J. DePiano Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Robert M. O'Connor Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Mark G Wallace Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
Fred G Choate Independent Director
Age: 66
Bio & Compensation  - Reuters
William L.G. Kwan Independent Director
Age: 71
Bio & Compensation  - Reuters
Lisa A Napolitano Independent Director
Age: 49
Bio & Compensation  - Reuters